Solulink, Inc. announced the completion of a new round of equity financing. The funds will enable Solulink to accelerate the commercialization of its HybriLink ‘any antibody in any color’ labeling technology. The HybriLink technology satisfies flow cytometrists’ unmet needs and enables antibody suppliers to address market demand for greater flow cytometry multiplexing ease and convenience.
The HybriLink technology solves the ‘missing color’ problem: the inability to find the needed antibody labeled with the right fluorophore (color). Often, the desired combination is not commercially available. By providing a simple way to mix and match any fluorophore with any antibody on demand, just-in-time at the point-of-use, HybriLink dramatically streamlines the development and expansion of multicolor flow panels for flow cytometry research labs. Solulink believes that HybriLink’s ability to offer all antibodies in all fluorophores – including the next generation of emerging fluorophores – resolves a fundamental challenge in flow cytometry and will expand the overall flow cytometry reagents market size.
“With the HybriLink technology, antibodies are labeled with a tag and the fluorophores labeled with a complimentary tag. These two components are then combined to form the labeled antibody, ready to use with nearly 100% efficiency. Labeled-antibody providers can now supply tagged antibodies and complimentary tagged fluorophores, which allow the user to create an unlimited number of labeled antibodies,” said Solulink’s CEO, David McCarty.
“Solulink’s HybriLink technology simultaneously fulfills two increasingly critical needs in flow cytometry: HybriLink offers flow cytometrists an easy way to create, or optimize, multi-color flow panels on demand by labeling any antibody with any color, without chemistry or chromatography. In addition, HybriLink offers strategic partners a radically simplified way to introduce new fluorophores into their library of labeled antibodies, while expanding their market potential.”
The company is currently providing early access to HybriLink products to select customers. Attractive licensing terms are available for licensees and commercial partners in the flow cytometry and antibody reagents markets.
“Flow cytometry instruments and fluorophores have advanced rapidly; however, antibody-labeling technology has stagnated and the few advances have not met user or market expectations,” added Mark Horne, CEO, Plymouth Ventures. “Based on our diligence results, we are confident that the HybriLink technology represents a major advancement for flow cytometry and will be embraced by the research community.”